- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00073905
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Palliative chemotherapy may improve the quality of life in patients who have locally advanced or metastatic biliary tract cancer and may help them live more comfortably.
PURPOSE: Phase II trial to study the effectiveness of adjuvant capecitabine and gemcitabine in improving quality of life in patients who have locally advanced or metastatic biliary tract cancer.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the ability of palliative capecitabine and gemcitabine to maintain or improve tumor-related symptoms (after treatable biliary duct obstruction has been relieved) as measured by the clinical benefit response in patients with locally advanced or metastatic biliary tract cancer.
Secondary
- Determine the clinical benefit response in patients treated with this regimen.
- Determine the time to and duration of clinical benefit response in patients treated with this regimen.
- Determine the objective response and time to progression in patients treated with this regimen.
- Determine the overall survival of patients treated with this regimen.
- Determine the quality of life of patients treated with this regimen.
- Determine the adverse events in patients treated with this regimen.
OUTLINE: This is an open-label, multicenter study.
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and oral capecitabine twice daily on days 1-14 (28 total doses). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive additional courses at the discretion of the investigator.
Quality of life is assessed at baseline, weekly during weeks 2-9 (courses 1-3), and then before each administration of gemcitabine.
Patients are followed every 3 months for 1 year and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 19-44 patients will be accrued for this study within 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
St. Gallen, Switzerland, CH-9007
- Kantonsspital - St. Gallen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed biliary tract cancer
- Locally advanced, unresectable, or metastatic disease
- Metastatic adenocarcinoma with clinical documentation of gallbladder or bile tree involvement with no evidence of another primary adenocarcinoma allowed
- Measurable or nonmeasurable disease
- Treatable biliary duct obstruction must be relieved by either internal endoscopic drainage/stenting or palliative bypass surgery before study entry
Symptomatic biliary tract cancer and has at least 1 of the following:
- Karnofsky 60-80%
- Baseline analgesic consumption at least 10 mg of morphine equivalents per day
- Baseline pain intensity score of at least 20 mm out of a possible 100 mm
- No prior or concurrent CNS metastasis
PATIENT CHARACTERISTICS:
Age
- 18 to 80
Performance status
- See Disease Characteristics
- Karnofsky 60-100%
Life expectancy
- Not specified
Hematopoietic
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10.0 g/dL
Hepatic
- Bilirubin no greater than 4 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 5 times ULN
- AST and ALT no greater than 5 times ULN
Renal
- Creatinine clearance greater than 50 mL/min
Cardiovascular
- No uncontrolled cardiovascular disease
Gastrointestinal
- Able to ingest oral medication
- No malabsorption syndrome
- No intractable nausea and/or vomiting
- No partial small bowel obstruction
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 1 year after study participation
- No active autoimmune disease
- No uncontrolled diabetes
- No known hypersensitivity to fluorouracil
- No known dihydropyrimidine dehydrogenase deficiency
- No definitive contraindication to corticosteroids
- No prior significant neurologic or psychiatric disorders (e.g., psychotic disorders, dementia, or seizures) that would preclude understanding or providing informed consent
- No prior severe reaction to fluoropyrimidine therapy
- No psychiatric disorder, cognitive dysfunction, or language problem that would preclude filling out the quality of life questionnaire or patient diary
- No other serious underlying medical condition that would preclude study participation
- No other malignancy within the past 5 years except nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy
- No prior immunotherapy
Chemotherapy
- No prior chemotherapy for advanced/metastatic disease
- No prior palliative chemotherapy
Endocrine therapy
- No concurrent megestrol
Radiotherapy
- More than 4 weeks since prior radiotherapy
No concurrent radiotherapy
- Treatment of a single painful lesion allowed
Surgery
- See Disease Characteristics
- Prior Whipple procedure allowed
- Prior duodenal bypass allowed
No concurrent endoscopic or external biliary drainage as a consequence of progressive malignant bile duct obstruction
- Drainage as a consequence of nonmalignant bile duct obstruction allowed
Other
- More than 30 days since prior treatment within a clinical study
- No other concurrent anticancer drugs
- No other concurrent investigational drugs
- No concurrent sorivudine or its chemically-related analogues (e.g., lamivudine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A
Capecitabine plus Gemcitabine
|
capecitabine plus gemcitabine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of palliative capecitabine and gemcitabine
Time Frame: 3 months
|
Determine the ability of palliative capecitabine and gemcitabine to maintain or improve tumor-related symptoms (after treatable biliary duct obstruction has been relieved) as measured by the clinical benefit response.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical benefit response alone as measured after 3 courses
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug 1;26(22):3695-701. doi: 10.1200/JCO.2007.15.6240.
- Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- pain
- advanced adult primary liver cancer
- recurrent adult primary liver cancer
- unresectable gallbladder cancer
- recurrent gallbladder cancer
- unresectable extrahepatic bile duct cancer
- recurrent extrahepatic bile duct cancer
- localized unresectable adult primary liver cancer
- adenocarcinoma of the gallbladder
- adenocarcinoma of the extrahepatic bile duct
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Gallbladder Diseases
- Biliary Tract Diseases
- Bile Duct Diseases
- Cholangiocarcinoma
- Liver Neoplasms
- Biliary Tract Neoplasms
- Gallbladder Neoplasms
- Bile Duct Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Capecitabine
Other Study ID Numbers
- SAKK 44/02
- EU-20322
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on capecitabine plus gemcitabine
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.TerminatedTriple Negative Breast CancerChina
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Asan Medical CenterCompleted
-
Rutgers, The State University of New JerseyRecruitingPancreatic CancerUnited States
-
Tata Memorial CentreRecruiting
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingCancer | Metastatic | Breast | Triple Negative | Disseminated Tumor CellUnited States
-
Assiut UniversityNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHER2 Positive Metastatic Breast CancerChina
-
NCIC Clinical Trials GroupTerminatedLiver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct CancerCanada
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina